ACADIA Pharmaceuticals (ACAD) : Traders are bullish on ACADIA Pharmaceuticals (ACAD) as it has outperformed the S&P 500 by a margin of 8.93% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 10.08%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 10.76% in the last 1 week, and is up 16.29% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
ACADIA Pharmaceuticals (NASDAQ:ACAD): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $36.35 and $35.65 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $37.06. The buying momentum continued till the end and the stock did not give up its gains. It closed at $36.55, notching a gain of 1.36% for the day. The total traded volume was 1,522,494 . The stock had closed at $36.06 on the previous day.
The stock has recorded a 20-day Moving Average of 10.06% and the 50-Day Moving Average is 5.74%. ACADIA Pharmaceuticals Inc. is up 7.44% in the last 3-month period. Year-to-Date the stock performance stands at 2.52%.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis, Alzheimers disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.